Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: AF-002JG/NP28761: A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated with Chemotherapy and Crizotinib

 


AF-002JG/NP28761: A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated with Chemotherapy and Crizotinib


Trial Focus

Lung Cancer

Objective

         This is a clinical trial of RO5424802 that will be administered by mouth which is investigational.

IRB Protocol #

13-2410

Trial Status

Archived

Principle Investigator

ROSS CAMIDGE

Sponsor

Hoffmann-LaRoche

Contact

AMY BROWN at (720)848-0603 or AMY.M.BROWN@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last as long as your disease does not worsen, you do not have severe side effects, and the study remains open. A follow up period will consist of clinic visit and/or phone contact. // Eligibility criteria include but are not limited to 18 years or older with lung cancer.Eligibility criteria include but are not limited to 18 years or older with lung cancer.